Efgartigimod for Guillain-Barré syndrome: a retrospective analysis of efficacy and safety.

Ther Adv Neurol Disord · 2026 · PMC12901846 · PMID 41696674

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Exploratory analysis of lymphocyte subsets suggested a decreasing trend in the proportions of CD3+CD4+ and CD4+HLA-DR+ T cells following efgartigimod treatment, with detailed results provided in the Supplemental Figures 1 and 2 and Supplemental Table 5 .

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.